US Patent 10,759,814 Crystal Forms Defined by X-ray Powder Diffraction Peaks: Scope, Claim Boundaries, and Patent Landscape
US Drug Patent 10,759,814 is a crystal-form patent that defines specific polymorphs (or closely related crystalline solids) of a “compound of the following formula,” by locking down the X-ray powder diffraction (XRPD) fingerprint using peak locations at defined 2θ values with a tight tolerance of ±0.2°. The independent claim structure is narrow but commercially potent: it can cover a marketed drug only if the active ingredient in the dosage form is that exact crystalline solid, not merely the same chemical entity. Dependent claims then further tighten the peak set and cover pharmaceutical compositions containing the claimed crystal.
Because the underlying chemical structure is not included in the prompt (the “compound of the following formula” is omitted), the claim-to-structure mapping, claim scope across salts/hydrates/solvates, and competitive freedom-to-operate analysis against other crystal estates cannot be completed accurately from the provided text alone.
What do the claims of US 10,759,814 cover in practice?
Short answer: The claims cover (1) specific crystalline solids defined by XRPD peak-position sets, and (2) dosage forms that include those solids.
Independent claim logic (claims 1, 4, 7)
- Claim 1: a crystal of the formula-compound where the XRPD spectrum has two or more peaks selected from a fixed list:
8.6±0.2°, 14.1±0.2°, 17.4±0.2°, 20.0±0.2°, 24.0±0.2°, 26.3±0.2°, 29.6±0.2°, 35.4±0.2°.
- Claim 4: a crystal of the same formula-compound where XRPD has two or more peaks selected from another fixed list:
4.4±0.2°, 8.9±0.2°, 11.7±0.2°, 14.9±0.2°, 22.3±0.2°, 24.4±0.2°, 28.0±0.2°, 31.5±0.2°.
- Claim 7: a crystal of the same formula-compound where XRPD has two or more peaks selected from yet another fixed list:
4.4±0.2°, 8.7±0.2°, 10.6±0.2°, 17.3±0.2°, 17.5±0.2°, 22.0±0.2°, 24.0±0.2°, 24.1±0.2°, 31.0±0.2°.
Practical boundary created by “two or more peaks”
Each independent claim requires at least two peaks within the selected list, but it does not require the full set. That increases enforceability breadth versus a claim that requires an exact full fingerprint, while still constraining the claimed solids to those that show at least a partial match to the authorized peak positions.
Dependent claims tighten the fingerprint to the full peak set
- Claim 2 locks claim 1 to crystals having all of the claim-1 list peaks (8.6, 14.1, 17.4, 20.0, 24.0, 26.3, 29.6, 35.4) within ±0.2°.
- Claim 5 locks claim 4 to crystals having all of its list peaks (4.4, 8.9, 11.7, 14.9, 22.3, 24.4, 28.0, 31.5) within ±0.2°.
- Claim 8 locks claim 7 to crystals having all of its list peaks (4.4, 8.7, 10.6, 17.3, 17.5, 22.0, 24.0, 24.1, 31.0) within ±0.2°.
Composition claims (claims 3, 6, 9)
- Claim 3: pharmaceutical composition comprising the claim-1 crystal plus a pharmaceutically acceptable carrier/diluent.
- Claim 6: composition with claim-4 crystal.
- Claim 9: composition with claim-7 crystal.
These are standard product-by-active-ingredient inclusion claims. They are enforceable against formulations if the marketed drug uses the claimed XRPD-defined crystal form.
How narrow or broad is the claim scope given the ±0.2° XRPD tolerance?
Short answer: Broad enough to capture variants that preserve two peaks, but tight enough to support “XRPD fingerprint” noninfringement defenses for alternative polymorphs.
Why ±0.2° matters
The claims specify peak positions to within ±0.2°. XRPD peak position depends on measurement conditions, instrumentation, calibration, sample preparation, and sample content (e.g., mixtures of forms). In litigation, that typically drives disputes over:
- diffractometer calibration and reference standards,
- instrument method (step size, time per step, scan range),
- background subtraction and smoothing,
- preferred orientation and particle size,
- whether the sample is a mixture and how peaks are deconvoluted.
The claim text itself remains strict: even if a polymorph is “similar,” it may fall outside ±0.2° for one or more key peaks.
“Two or more peaks selected from [a list]” vs full-set dependent claims
- Independent claims: a crystal can satisfy the claim even if it lacks 6 of 8 (or 7 of 9) possible peaks, as long as it hits at least two within ±0.2°.
- Dependent claims: require the full list, reducing the probability that a near-polymorph design-around remains noninfringing.
This dual structure is a standard patent strategy: broaden independent coverage for partial fingerprint matches and ladder narrower dependent claims for stronger validity and infringement positioning.
Which crystal forms are implicated by the three XRPD peak lists?
Short answer: At least three distinct crystalline “species” are implied by the separated peak lists, with overlap in some low-angle peaks.
Overlap and implied relationships across claims
- Both claim 4 and claim 7 include a 4.4±0.2° peak in their respective lists.
- Both claim 1 and claim 4 include peaks around the mid-low angles (e.g., 14.1 vs 14.9), but not the same values.
- Claim 7 has both 17.3±0.2° and 17.5±0.2°, indicating either two resolvable peaks or a split peak pattern that can distinguish it from claim 4 and claim 1.
This structure suggests the patent may cover multiple polymorphs (or polymorph families) of the same molecule, each characterized by a signature XRPD profile.
What is not claimed based on the provided text
The claim set provided does not, on its face, explicitly recite:
- hydrate forms,
- solvate forms,
- amorphous content,
- specific particle size distributions,
- specific manufacturing steps.
If those exist in the specification, they are not reflected in the claim text supplied. As provided, the legal test is XRPD peak positions.
What pharmaceutical compositions are covered and what product forms are likely within scope?
Short answer: Any pharmaceutical composition in which the active ingredient is the XRPD-defined crystal and the composition includes a pharmaceutically acceptable carrier or diluent.
Covered drug products
Claims 3/6/9 are not limited by:
- dosage form (tablet, capsule, film-coated tablet, powder-in-capsule, granulate),
- route of administration,
- strength or excipient identity,
- processing method.
So scope attaches to the active crystalline solid used in manufacturing.
Key limitation
The claims require the presence of the claimed crystal form. A formulation using a different polymorph (even if it contains the same chemical formula-compound) should avoid literal infringement if XRPD peak positions fall outside the listed ±0.2° bands and the “two or more peaks” selection cannot be satisfied.
How would a generic or reformulation developer assess infringement risk against US 10,759,814?
Short answer: Compare the XRPD of the candidate solid against all three peak lists and check both independent and dependent claim match thresholds.
Stepwise infringement screening framework
- Identify the active solid in the candidate drug substance (not the finished blend).
- Measure XRPD under calibrated conditions and report peak positions with measurement uncertainty.
- Check independent claim match:
- Claim 1: any two peaks among the eight listed values present at ±0.2°.
- Claim 4: any two peaks among its eight listed values present at ±0.2°.
- Claim 7: any two peaks among its nine listed values present at ±0.2°.
- Check dependent claim match:
- Does the candidate show the complete set of peaks (all values) in the relevant list within ±0.2°?
- If mixture: determine whether the candidate contains the claimed crystal as a distinct phase with detectable peaks, and whether deconvolution supports meeting the claim “peaks selected from” threshold.
Design-around levers
- Select or manufacture an alternative polymorph with at least one critical peak shifted beyond ±0.2°.
- Ensure the marketed solid lacks sufficient peaks from each list to reach “two or more” for any one independent claim.
- Avoid the specific crystalline phase even as a minor component, if it is detectable and claim-matching.
What patent landscape can be concluded from the claim text alone?
Short answer: Only the subject-matter class (XRPD-defined polymorph and composition). Full landscape mapping across related patents, assignees, and family members cannot be reliably produced from the prompt.
The provided text does establish:
- the patent is crystal/polymorph-centric, likely based on XRPD characterization,
- the estate likely includes additional claims in the same patent or family covering other variants (hydrates/solvates/particle sizes), but those are not shown in the provided excerpt,
- enforcement and validity will hinge on crystallography evidence: XRPD peak positions, peak intensity, and reproducibility.
No claim numbers, specification disclosures, family members, priority dates, expiration dates, litigation posture, or Orange Book listings are included in the prompt. Without that, a complete “patent landscape” (other patents in the same family, other players, and expiration timeline) would be incomplete.
Key takeaways
- US 10,759,814 covers three XRPD-defined crystalline solids of a specific formula-compound, plus pharmaceutical compositions containing each crystal.
- Independent claims require XRPD to show two or more peaks (within ±0.2°) from a defined list, making the scope broader than a “full fingerprint” claim.
- Dependent claims require the full set of listed peaks, narrowing infringement targets to crystals matching a stricter fingerprint.
- Product-by-crystal claims mean formulation infringement risk is driven by the polymorph used in the drug substance, not excipients or dosage form.
- A noninfringement strategy depends on XRPD peak displacement beyond ±0.2° and ensuring no independent claim list provides at least two matching peaks.
FAQs
1) Does US 10,759,814 require an exact full XRPD profile to infringe?
No. Independent claims (1/4/7) require at least two peaks within the specified ±0.2° bands from the listed values. Dependent claims (2/5/8) require the complete set for stronger coverage.
2) Can a formulation avoid infringement by using a different particle size or processing method?
If the processing changes the polymorph (or peak positions beyond ±0.2°), it can reduce risk. If it only changes particle size without changing the crystalline phase and peak positions, it may not avoid meeting the XRPD-based claim limitations.
3) Are amorphous or partially crystalline forms covered?
The provided claims require a “crystal” and XRPD peak matches. A fully amorphous solid should not meet the peak-position requirements. Partially crystalline mixtures create fact issues around detection and whether the claimed peaks are present within ±0.2°.
4) Do the composition claims cover any dosage form?
Yes, based on the provided claim text, since claims 3/6/9 only require a pharmaceutical composition including the claimed crystal plus a pharmaceutically acceptable carrier/diluent, without limiting dosage form.
5) What is the most practical infringement test for the claimed crystals?
Run XRPD on the drug substance and compare peak positions against each of the three peak lists, under validated calibration, checking both independent “two or more peaks” thresholds and dependent “all peaks” requirements.
References
- US Patent 10,759,814 (claims provided in prompt).
